MRNY YIELDMAX MRNA OPTION INCOME STRATEGY ETF
- 8.821
- -0.109-1.22%
Brookline Capital Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $238
Moderna Continues to Decline as Oppenheimer Latest to Downgrade
Moderna Is Maintained at Hold by TD Cowen
BofA Securities Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $110
Moderna Cut to Underweight From Neutral by JP Morgan
Moderna Price Target Cut to $70.00/Share From $88.00 by JP Morgan
A Quick Look at Today's Ratings for Moderna(MRNA.US), With a Forecast Between $94 to $125
Piper Sandler Maintains Overweight on Moderna, Lowers Price Target to $115
Moderna Analyst Ratings
Brookline Capital Cuts Price Target on Moderna to $238 From $310
RBC Capital lowered its target price for Moderna to $75.
RBC Cuts Price Target on Moderna to $75 From $90, Keeps Sector Perform Rating
Brookline Capital Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $310
Street Calls of the Week: Moderna Upgraded, Downgrade for Hershey
Moderna Analyst Ratings
HSBC Upgrades Moderna(MRNA.US) to Hold Rating, Cuts Target Price to $82
HSBC Upgrades Moderna to Hold From Reduce, Price Target Is $82
Piper Sandler Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $157
Redburn Atlantic Adjusts Moderna Price Target to $102 From $117
Argus Research Maintains Moderna(MRNA.US) With Buy Rating